Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,801,492
-
Share change
-
-855,389
-
Total reported value
-
$1,039,173
-
Put/Call ratio
-
235%
-
Price per share
-
$0.27
-
Number of holders
-
44
-
Value change
-
-$159,214
-
Number of buys
-
15
-
Number of sells
-
26
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q4 2023
As of 31 Dec 2023,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,801,492 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, LIBERTY WEALTH MANAGEMENT LLC, Weaver Consulting Group, ABNER HERRMAN & BROCK LLC, RAYMOND JAMES & ASSOCIATES, STATE STREET CORP, Ikarian Capital, LLC, and Virtu Financial LLC.
This page lists
44
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.